Sanofi S.A. (SNY)
| Market Cap | 117.23B |
| Revenue (ttm) | 45.57B |
| Net Income (ttm) | 15.02B |
| Shares Out | 1.25B |
| EPS (ttm) | 1.94 |
| PE Ratio | 24.02 |
| Forward PE | 12.25 |
| Dividend | $3.53 |
| Dividend Yield | 7.58% |
| Trading Day | March 5 |
| Last Price | $46.59 |
| Previous Close | $45.90 |
| Change ($) | 0.69 |
| Change (%) | 1.50% |
| Day's Open | 46.20 |
| Day's Range | 46.01 - 46.65 |
| Day's Volume | 3,172,319 |
| 52-Week Range | 37.62 - 55.00 |
The FDA accepts Sanofi's (SNY) sBLA for review of Dupixent for treating moderate-to-severe asthma in children aged six-11 years. A verdict from the FDA is expected on Oct 21, 2021.
The FDA has accepted for review the supplemental marketing application seeking approval for Dupixent (dupilumab). It is an add-on treatment for children aged 6 to 11 years with uncontrolled mo...
Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK'...
Health Canada has approved Sanofi's SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis i...
MUNICH--(BUSINESS WIRE)-- #AAV--SIRION Biotech announced that it signed a license and collaboration agreement with Sanofi.
The FDA approved expanded use of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi's SA (NASDAQ: SNY) immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced l...
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règ...
Sanofi and GlaxoSmithKline PLC (LON:GSK) have announced details of a phase II study for their collaborative coronavirus vaccine. Britain's Glaxo and France's Sanofi are the world's two largest...
The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an "insufficient" immune response to the virus in people older than 50...
Sanofi SA (NASDAQ: SNY)and GlaxoSmithKline Plc (NYSE: GSK) have initiated a new Phase 2 study with 720 volunteers aged 18 and finalize the antigen dosage for Phase 3 evaluation of their adjuva...
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Bristol-Myers Squibb Co (NYSE: BMY) and Sanofi SA (NASDAQ: SNY) were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blood-thinning drug Plavix, Bloombe...
A judge in Hawaii on Monday ordered Bristol-Myers Squibb Co and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its bl...
A COVID-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio "will not be ready this year," the French drugmaker's chief executive told Le Journal du Dimanche newspaper.
Sanofi SA (NASDAQ: SNY) has launched a takeover offer for Kiadis Pharma NV (OTC: KIADF) to represent an aggregate adjusted equity value of €308 million. The takeover offer is priced at €5.45 p...
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, A...
The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell car...
Sanofi CEO says Dupixent eczema drug is game-changing for company
"This is a once in a generation medicine," Sanofi CEO Paul Hudson said of Dupixent, a therapy for allergic diseases such as eczema, asthma and nasal polyps that's seeing rapid sales growth.
Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter
Shares of Sanofi (NASDAQ:SNY) rose 2.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 3.33% over the past year to $1.45, which may not ...
Sanofi SA (NASDAQ: SNY) posted a profit for the fourth quarter of 2020 at €1.08 billion, a turnaround from a loss of €10 million a year ago. However, sales came at €9.38 billion, down 2.4% yea...
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.
Sanofi to help produce doses of Pfizer-BioNTech Covid vaccine
CNBC's Charlotte Reed reports on Sanofi lending a hand to produce 125 million doses of the Pfizer-BioNTech Covid-19 vaccine after it suffered a setback in the development of its own vaccine.
Unusual collaboration will see Sanofi supply more than 125 million doses of Pfizer–BioNTech COVID shot from the summer.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règ...
Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe
Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend. Dupixent and flu vaccine sales growth boosted revenue in the latest quarter and the deep drug pipeline is ...
Part 2 of the series will search the European market for value. Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend.
Sanofi (SNY) CEO Paul Hudson Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)
After divesting its active pharmaceutical ingredient segment, the slimmed-down company will have more time to focus on developing new blockbuster drugs.
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
The Invesco European Growth Fund (Trades, Portfolio) disclosed last week that its top five trades during the fiscal fourth quarter included new holdings in Heineken NV (XAMS:HEIA), TGS-NOPEC G...
Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.
Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.
French drugmaker Sanofi has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals as it belatedly expands in a fast-growing medical area.
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
Wide-Moat Stocks On Sale - The January 2021 Heat Map
These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softe...
About SNY
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for... [Read more...]
| Industry Drug Manufacturers-General | |
| CEO Paul Hudson | Employees 99,412 |
| Stock Exchange NASDAQ | Ticker Symbol SNY |
Financial Performance
In 2020, Sanofi's revenue was 37.37 billion, a decrease of -0.70% compared to the previous year's 37.63 billion. Earnings were 12.31 billion, an increase of 338.85%.
Analyst Forecasts
According to 7 analysts, the average rating for Sanofi stock is "Buy." The 12-month stock price forecast is 64.67, which is an increase of 38.81% from the latest price.